ATE370225T1 - Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen - Google Patents

Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen

Info

Publication number: ATE370225T1
Authority: AT; Austria
Prior art keywords: cells; differentiation; neuronal; bone marrow; inducing
Prior art date: 2000-02-11

Application number

AT01909061T

Other languages

English (en)

Inventor

Ira Black

Dale Woodbury

Darwin Prockop

Emily Schwartz

Original Assignee

Philadelphia Health & Educatio

Univ New Jersey Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-11

Filing date

2001-02-09

Publication date

2007-09-15

2001-02-09 Application filed by Philadelphia Health & Educatio, Univ New Jersey Med filed Critical Philadelphia Health & Educatio

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370225T1 publication Critical patent/ATE370225T1/de

Links

210000002569 neuron Anatomy 0.000 title abstract 3
230000004069 differentiation Effects 0.000 title abstract 2
210000002798 bone marrow cell Anatomy 0.000 title 1
230000001939 inductive effect Effects 0.000 abstract 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 2
210000004271 bone marrow stromal cell Anatomy 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000004031 neuronal differentiation Effects 0.000 abstract 2
239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
239000004322 Butylated hydroxytoluene Substances 0.000 abstract 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
239000003963 antioxidant agent Substances 0.000 abstract 1
235000006708 antioxidants Nutrition 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
229960005070 ascorbic acid Drugs 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 1
229940095259 butylated hydroxytoluene Drugs 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
238000002659 cell therapy Methods 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
229960004419 dimethyl fumarate Drugs 0.000 abstract 1
LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
229960001760 dimethyl sulfoxide Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
238000001415 gene therapy Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/815—Dopamine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Physical Education & Sports Medicine (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Immunology (AREA)
Psychology (AREA)
Dermatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT01909061T 2000-02-11 2001-02-09 Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen ATE370225T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18185000P	2000-02-11	2000-02-11

Publications (1)

Publication Number	Publication Date
ATE370225T1 true ATE370225T1 (de)	2007-09-15

Family

ID=22666063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01909061T ATE370225T1 (de)	2000-02-11	2001-02-09	Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen

Country Status (10)

Country	Link
US (3)	US7279331B2 (de)
EP (2)	EP1272614B1 (de)
JP (1)	JP2003521935A (de)
AT (1)	ATE370225T1 (de)
AU (2)	AU3685401A (de)
CA (1)	CA2399623A1 (de)
DE (1)	DE60129943T2 (de)
ES (1)	ES2292564T3 (de)
HK (1)	HK1052369B (de)
WO (1)	WO2001059072A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19853487A1 (de)	1998-11-19	2000-05-25	Fumapharm Ag Muri	Verwendung von Dialkylfumaraten
AU3685401A (en) *	2000-02-11	2001-08-20	Philadelphia Health	Differentiation of bone marrow cells into neuronal cells and uses therefor
US20030104997A1 (en) *	2001-09-05	2003-06-05	Black Ira B.	Multi-lineage directed induction of bone marrow stromal cell differentiation
US9969980B2 (en)	2001-09-21	2018-05-15	Garnet Biotherapeutics	Cell populations which co-express CD49c and CD90
EP1452586B1 (de) *	2001-10-30	2012-05-30	Nc Medical Research Inc.	Verfahren zur induktion der differenzierung mesodermaler stammzellen zu zellen des nervensystems
WO2003060082A2 (en)	2002-01-14	2003-07-24	The Board Of Trustees Of The University Of Illinois	Use of modified pyrimidine compounds to promote stem cell migration and proliferation
CA2475288C (en)	2002-02-06	2014-09-02	Sanbio, Inc.	Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
US9969977B2 (en) *	2002-09-20	2018-05-15	Garnet Biotherapeutics	Cell populations which co-express CD49c and CD90
US9572840B2 (en)	2003-06-27	2017-02-21	DePuy Synthes Products, Inc.	Regeneration and repair of neural tissue using postpartum-derived cells
US7875272B2 (en)	2003-06-27	2011-01-25	Ethicon, Incorporated	Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en)	2003-06-27	2017-03-14	DePuy Synthes Products, Inc.	Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8518390B2 (en)	2003-06-27	2013-08-27	Advanced Technologies And Regenerative Medicine, Llc	Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
ES2569780T3 (es)	2003-06-27	2016-05-12	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
US8491883B2 (en)	2003-06-27	2013-07-23	Advanced Technologies And Regenerative Medicine, Llc	Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8790637B2 (en)	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
DK1663197T3 (da)	2003-09-09	2008-01-07	Fumapharm Ag	Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
ES2621847T3 (es)	2004-12-23	2017-07-05	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
CA2589063C (en)	2004-12-23	2016-08-09	DePuy Synthes Products, Inc.	Treatment of parkinson's disease and related disorders using postpartum derived cells
EP1855700B1 (de)	2005-03-07	2013-10-30	SanBio, Inc.	Verwendung von neuronalen vorläuferzellen zur behandlung von läsionen des zentralnervensystems
US9427419B2 (en)	2005-09-12	2016-08-30	Abela Pharmaceuticals, Inc.	Compositions comprising dimethyl sulfoxide (DMSO)
WO2007033180A1 (en)	2005-09-12	2007-03-22	Abela Pharmaceuticals, Inc.	Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US8480797B2 (en)	2005-09-12	2013-07-09	Abela Pharmaceuticals, Inc.	Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
AU2006291134C1 (en)	2005-09-12	2013-08-15	Abela Pharmaceuticals, Inc.	Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US9175261B2 (en)	2005-12-16	2015-11-03	DePuy Synthes Products, Inc.	Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
ES2391034T3 (es)	2005-12-19	2012-11-20	Ethicon, Inc.	Expansión in vitro de células derivadas postparto en frascos rotatorios
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
KR100814504B1 (ko)	2006-11-03	2008-03-18	전북대학교산학협력단	골수 간엽 줄기세포를 신경세포로 분화시키는 방법
HUE032251T2 (en) *	2007-02-08	2017-09-28	Biogen Ma Inc	Neuroprotection in demyelinating diseases
EP2653873B8 (de)	2007-02-08	2022-08-24	Biogen MA Inc.	Zusammensetzungen und deren Verwendung zur Behandlung von Multipler Sklerose
US8354370B2 (en)	2007-06-15	2013-01-15	Garnet Biotherapeutics, Inc.	Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders
EP2203186B1 (de)	2007-10-05	2014-09-24	DePuy Synthes Products, LLC	Reparatur und regeneration von nierengewebe mit zellen aus menschlicher nabelschnur
WO2009057111A2 (en) *	2007-10-29	2009-05-07	Hadasit Medical Research Services & Development Limited	Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
ES2787513T3 (es)	2007-12-03	2020-10-16	Sanbio Inc	Métodos y composiciones para modular la diferenciación de células pluripotenciales
US8236538B2 (en)	2007-12-20	2012-08-07	Advanced Technologies And Regenerative Medicine, Llc	Methods for sterilizing materials containing biologically active agents
BRPI0921494A2 (pt)	2008-11-03	2018-10-30	Prad Reasearch And Development Ltd	método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US10557116B2 (en)	2008-12-19	2020-02-11	DePuy Synthes Products, Inc.	Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en)	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
PL2411504T3 (pl)	2009-03-26	2017-10-31	Depuy Synthes Products Inc	Komórki ludzkiej tkanki pępowinowej jako terapia choroby Alzheimera
WO2011047289A1 (en)	2009-10-16	2011-04-21	University Of Medicine And Dentistry Of New Jersey	Closed system separation of adherent bone marrow stem cells for regenerative medicine applications
US9109206B2 (en)	2009-10-16	2015-08-18	Rutgers, The State University Of New Jersey	Method for treating chronic nerve tissue injury using a cell therapy strategy
US9855212B2 (en)	2009-10-30	2018-01-02	Abela Pharmaceuticals, Inc.	Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
WO2012156968A2 (en)	2011-05-19	2012-11-22	Ariel - University Research And Development Company, Ltd.	Use of mesenchymal stem cells for the improvement of affective and cognitive function
US8921533B2 (en)	2011-07-25	2014-12-30	Chromatin Technologies	Glycosylated valproic acid analogs and uses thereof
KR101981450B1 (ko)	2011-12-23	2019-08-28	디퍼이 신테스 프로덕츠, 인코포레이티드	인간 제대 조직-유래된 세포의 검출

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5405772A (en)	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US5639618A (en) *	1994-05-13	1997-06-17	Plurion, Inc.	Method of isolating a lineage specific stem cell in vitro
WO1996030031A1 (en)	1995-03-28	1996-10-03	Thomas Jefferson University	Isolated stromal cells and methods of using the same
US6653134B2 (en) *	1995-03-28	2003-11-25	Cp Hahnemann University	Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6090622A (en) *	1997-03-31	2000-07-18	The Johns Hopkins School Of Medicine	Human embryonic pluripotent germ cells
EP1096941B1 (de) *	1998-05-07	2005-08-10	University Of South Florida	Knochenmarkszellen als quelle von neuronen zur wiederherstellung von gehirn und knochenmark
AU3685401A (en) *	2000-02-11	2001-08-20	Philadelphia Health	Differentiation of bone marrow cells into neuronal cells and uses therefor
WO2001083715A2 (en) *	2000-05-01	2001-11-08	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary,	Derivation of midbrain dopaminergic neurons from embryonic stem cells

2001
- 2001-02-09 AU AU3685401A patent/AU3685401A/xx active Pending
- 2001-02-09 CA CA002399623A patent/CA2399623A1/en not_active Abandoned
- 2001-02-09 AT AT01909061T patent/ATE370225T1/de not_active IP Right Cessation
- 2001-02-09 ES ES01909061T patent/ES2292564T3/es not_active Expired - Lifetime
- 2001-02-09 EP EP01909061A patent/EP1272614B1/de not_active Expired - Lifetime
- 2001-02-09 WO PCT/US2001/004282 patent/WO2001059072A1/en not_active Ceased
- 2001-02-09 JP JP2001558212A patent/JP2003521935A/ja active Pending
- 2001-02-09 HK HK03104584.1A patent/HK1052369B/en not_active IP Right Cessation
- 2001-02-09 EP EP06012529A patent/EP1749884A1/de not_active Withdrawn
- 2001-02-09 DE DE60129943T patent/DE60129943T2/de not_active Expired - Lifetime
- 2001-02-09 AU AU2001236854A patent/AU2001236854B2/en not_active Ceased
2002
- 2002-08-06 US US10/213,526 patent/US7279331B2/en not_active Expired - Fee Related
2007
- 2007-09-04 US US11/849,870 patent/US8486698B2/en not_active Expired - Fee Related
2013
- 2013-07-11 US US13/939,986 patent/US20130302889A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2003521935A (ja)	2003-07-22
WO2001059072A1 (en)	2001-08-16
US8486698B2 (en)	2013-07-16
EP1272614A4 (de)	2003-05-07
EP1272614A1 (de)	2003-01-08
HK1052369A1 (en)	2003-09-11
US20030203484A1 (en)	2003-10-30
DE60129943T2 (de)	2008-05-08
EP1749884A1 (de)	2007-02-07
HK1052369B (en)	2007-12-21
ES2292564T3 (es)	2008-03-16
US20130302889A1 (en)	2013-11-14
US7279331B2 (en)	2007-10-09
AU3685401A (en)	2001-08-20
CA2399623A1 (en)	2001-08-16
AU2001236854B2 (en)	2005-04-14
DE60129943D1 (de)	2007-09-27
US20080131407A1 (en)	2008-06-05
EP1272614B1 (de)	2007-08-15

Legal Events

Date	Code	Title	Description
2008-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60129943D1 (de)	2007-09-27	Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
Willner et al.	1981	Chronic GM2 gangliosidosis masquerading as atypical Friedreich ataxia: clinical, morphologic, and biochemical studies of nine cases
WO2003020908A3 (en)	2003-06-05	Multi-lineage directed induction of bone marrow stromal cell differentiation
ATE323180T1 (de)	2006-04-15	Katalytische nukleinsäure und deren medizinische verwendung
WO2003066072A3 (en)	2004-06-17	Cell therapy using immunoregulatory t-cells
Sultan et al.	2021	Dental pulp stem cells stimulate neuronal differentiation of PC12 cells
Maldonado-Soto et al.	2014	Stem cells in the nervous system
ATE482267T1 (de)	2010-10-15	Tierzellen und verfahren für die replikation von influenza viren
BR9408025A (pt)	1996-12-17	Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
PT751939E (pt)	2002-11-29	Naftilamidas como agentes para o sistema nervoso central
WO2006060709A3 (en)	2006-07-06	Biological pathways in progenitor cells
DE60044655D1 (de)	2010-08-19	Angereicherte Zellpopulationen des zentralen Nervensystems
NZ509387A (en)	2002-10-25	Subjecting T-cells to oxidative stress so as to induce an altered cytokine production profile and a reduced proliferative response
DE69934987D1 (de)	2007-03-15	Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
ATE485377T1 (de)	2010-11-15	Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
Ben-Hur et al.	2006	Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells
EA200100342A1 (ru)	2001-10-22	Связывающие соединения адгезионной молекулы нервной клетки
DE60120682D1 (de)	2006-07-27	Therapeutische verwendung mesenchymaler stromazellen
WO2004043990A3 (en)	2005-02-03	Human stem cell materials and methods
ATE400654T1 (de)	2008-07-15	Neues säugetiergen bc1-w, welches zur bc1-2 familie apoptose-kontrollierender gene gehört
WO2001042784A3 (en)	2001-12-13	Methods for screening compounds active on neurons
ATE243741T1 (de)	2003-07-15	Zufuhr von genprodukten mittels mesangium-zellen
HUT69990A (en)	1995-09-28	Method and composition for determining the immunological activity of bioactive substances
BRPI0409683A (pt)	2006-04-18	5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
Rodríguez‐Serrano et al.	2010	Promotion of human adipose‐derived stem cell proliferation mediated by exogenous nucleosides